Cancer stem cells in oesophageal squamous cell carcinoma: Identification, prognostic and treatment perspectives

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 9-19

  Islam, Farhadul ^a   Gopalan, Vinod ^a   Wahab, Riajul ^a   Smith, Robert A ^a   Lam, Alfred K Y ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Cancer stem cell; CSC biology; CSC markers; Oesophageal squamous cell carcinoma

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CD271 ANTIGEN; CELL MARKER; HERMES ANTIGEN; LYMPHOCYTE ANTIGEN; NUCLEIC ACID BINDING PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; PODOPLANIN; PROTEIN HIWI; SAL LIKE PROTEIN 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; ISOENZYME; POU5F1 PROTEIN, HUMAN; PROM1 PROTEIN, HUMAN; RETINAL DEHYDROGENASE; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CARCINOGENESIS; CELL FATE; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS SURGERY; GENE EXPRESSION PROFILING; HUMAN; METASTASIS; NEXT GENERATION SEQUENCING; NONHUMAN; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIDE POPULATION CELL; TUMOR INVASION; CARCINOMA, SQUAMOUS CELL; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGEAL NEOPLASMS; PATHOLOGY; PHYSIOLOGY; PROGNOSIS;

AC133 ANTIGEN; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; ISOENZYMES; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PROGNOSIS; RETINAL DEHYDROGENASE; SOXB1 TRANSCRIPTION FACTORS;

EID: 84942192030     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.04.007     Document Type: Review

References (125)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Lam K.Y., Law S., Tung P.H., Wong J. Esophageal basaloid squamous cell carcinoma: an unique clinicopathological entity with telomerase activity as a prognostic indicator. J Pathol 2001, 195:435-442.
3. Lam K.Y., Law S.Y.K., Loke S.L., Fok M., Ma L.T. Double sarcomatoid carcinomas of the esophagus. Path Res Pract 1996, 192:604-609.
4. Lam K.Y., Dickens P., Loke S.L., Fok M., Ma L., Wong J. Squamous cell carcinoma of the esophagus with mucin-secreting component (mucoepidermoid carcinoma and adenosquamous cell carcinoma): a clinicopathologic study and a review of literature. Eur J Surg Oncol 1994, 20:25-31.
5. Law S.Y.K., Fok M., Lam K.Y., Loke S.L., Ma L.T., Wong J. Small cell carcinoma of the esophagus. Cancer 1994, 73:2894-2899.
6. Lam K.Y., Ma L. Pathology of esophageal cancers: local experience and current insights. Chin Med J 1997, 110:459-464.
7. Lam A.K.Y. Critical review: molecular biology of esophageal squamous cell carcinoma. Crit Rev Oncol Hematol 2000, 33:71-90.
8. Chow V., Law S., Lam K.Y., Luk J.M., Wong J. Telomerase activity in small cell esophageal carcinoma. Dis Esophagus 2001, 14:139-142.
9. Lam K.Y., Law S., Tung P.H., Wong J. Esophageal small cell carcinoma: clinicopathologic parameters, p53 overexpression, proliferative marker, and their impact on pathogenesis. Arch Pathol Lab Med 2000, 124:228-233.
10. Lam K.Y., Tsao S.W., Zhang D., Law S., He D., Ma L., et al. Prevalence and predictive value of p53 mutation in patients with esophageal squamous cell carcinomas: a prospective clinicopatholgical study and survival analysis of 70 patients. Int J Cancer 1997, 74:212-219.
11. Chan D., Tsoi M.Y., Liu C.D., Chan S.H., Law S.Y., Chan K.W., et al. Oncogene GAEC1 regulates CAPN10 expression which predicts survival in esophageal squamous cell carcinoma. World J Gastroenterol 2013, 19:2772-2780.
12. Lam K.Y., Law S., Lo T., Tung H.M., Wong J. The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients. Am J Gastroenterol 1999, 94:2060-2068.
13. Lam K.Y., Law S.Y.K., So M.K.P., Fok M., Ma L.T., Wong J. Prognostic implication of proliferative markers MIB-1 and PC 10 in esophageal squamous cell carcinoma. Cancer 1996, 77:7-13.
14. Tong D.K., Law S., Kwong D.L., Chan K.W., Lam A.K., Wong K.H. Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol 2010, 17:2184-2192.
15. Lam K.Y., Law S., Ma L.T., Ong S.K., Wong J. Pre-operative chemotherapy for squamous cell carcinoma of the esophagus: do histological assessment and p53 overexpression predict chemo-responsiveness. Eur J Cancer 1997, 33:1221-1225.
16. Launois B., Delarue D., Campion J.P., Kerbaol M. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981, 153:690-692.
17. Hayashi Y., Nishida T., Tsujii M., Tsutsui S., Yamamoto K., Isohashi F., et al. Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma. BMC Cancer 2014, 14:706.
18. Arnott S.J., Duncan W., Kerr G.R., Walbaum P.R., Cameron E., Jack W.J., et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992, 24:108-113.
19. Nygaard K., Hagen S., Hansen H.S., Hatlevoll R., Hultborn R., Jakobsen A., et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicentre study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992, 16:1104-1110.
20. He L., Allen P.K., Potter A., Wang J., Chang J.Y., Gomez D.R., et al. Re-evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma. J Thorac Oncol 2014, 9:1398-1405.
21. Cao X.F., He X.T., Ji L., Xiao J., Lv J. Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinoma. Dis Esophagus 2009, 22:477-481.
22. Yano T., Muto M., Minashi K., Iwasaki J., Kojima T., Fuse N., et al. Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer 2012, 131:1228-1234.
23. Arnott S.J., Duncan W., Gignoux M., Hansen H.S., Launois B., Nygaard K., et al. Preoperative radiotherapy for esophageal carcinoma. Cochrane Database Syst Rev 2005, 4:CD001799.
24. Bao Y., Liu S., Zhou Q., Cai P., Anfossi S., Li Q., et al. Three-dimensional conformal radiotherapy with concurrent chemotherapy for postoperative recurrence of esophageal squamous cell carcinoma: clinical efficacy and failure pattern. Radiat Oncol 2013, 8:241.
25. Yano T., Muto M., Minashi K., Onozawa M., Nihei K., Ishikura S., et al. Long-term results of salvage photodynamic therapy for patients with local failure after chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 2011, 43:657-663.
26. Lecleire S., Di Fiore F., Antonietti M., Ben-Soussan E., Hochain P., Lerebours E., et al. Nonoperable patients with superficial esophageal cancer treated by photodynamic therapy after chemoradiotherapy have more severe complications than patients treated in primary intent. Am J Gastroenterol 2008, 103:2215-2219.
27. Vermeulen L., de Sousa e Melo F., Richel D.J., Medema J.P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012, 13:e83-e89.
28. Li S., Yue D., Chen X., Wang L., Li J., Ping Y., et al. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. Oncol Rep 2015, 33:425-432.
29. Sun S.J., Feng L., Zhao G.Q., Dong Z.M. HAX-1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells. Dig Dis Sci 2012, 57:1838-1846.
30. Francipane M.G., Chandler J., Lagasse E. Cancer stem cells: a moving target. Curr Pathobiol Rep 2013, 1:111-118.
31. Mori R., Ishiguro H., Kuwabara Y., Kimura M., Mitsui A., Tomoda K., et al. Targeting beta1 integrin restores sensitivity to docetaxel of esophageal squamous cell carcinoma. Oncol Rep 2008, 20:1345-1351.
32. Wang G., Liu L., Sharma S., Liu H., Yang W., Sun X., et al. Bmi-1 confers adaptive radioresistance to KYSE-150R esophageal carcinoma cells. Biochem Biophys Res Commun 2012, 425:309-314.
33. Williams K., Motiani K., Giridhar P.V., Kasper S. CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches. Exp Biol Med (Maywood) 2013, 238:324-338.
34. Alison M.R., Lin W.R., Lim S.M., Nicholson L.J. Cancer stem cells: in the line of fire. Cancer Treat Rev 2012, 38:589-598.
35. Liu J., Fan H., Ma Y., Liang D., Huang R., Wang J., et al. Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One 2013, 8:e56141.
36. Zhang J.X., Tong Z.T., Yang L., Wang F., Chai H.P., Zhang F., et al. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma. Int J Cancer 2013, 132:2567-2577.
37. Zhu W., You Z., Li T., Yu C., Tao G., Hu M., et al. Correlation of hedgehog signal activation with chemoradiotherapy sensitivity and survival in esophageal squamous cell carcinomas. Jpn J Clin Oncol 2011, 41:386-393.
38. Okumura H., Uchikado Y., Setoyama T., Matsumoto M., Owaki T., Ishigami S., et al. Biomarkers for predicting the response of esophageal squamous cell carcinoma to neoadjuvant chemoradiation therapy. Surg Today 2014, 44:421-428.
39. Swords R., Quinn J., Fay M., O'Donnell R., Goldman J., Murphy P.T. CML clonal evolution with resistance to single agent imatinib therapy. Clin Lab Haematol 2005, 27:347-349.
40. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol 2010, 20:85-92.
41. Lou H., Dean M. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 2007, 26:1357-1360.
42. Eramo A., Lotti F., Sette G., Pilozzi E., Biffoni M., Di Virgilio A., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2007, 15:504-514.
43. Mak A.B., Blakely K.M., Williams R.A., Penttilä P.A., Shukalyuk A.I., Osman K.T., et al. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem 2011, 286:41046-41056.
44. Waldron N.N., Kaufman D.S., Oh S., Inde Z., Hexum M.K., Ohlfest J.R., et al. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer. Mol Cancer Ther 2011, 10:1829-1838.
45. Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H., Jones D.L., et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
46. Islam F., Qiao B., Smith R.A., Gopalan V., Lam A.K. Cancer stem cell: fundamental experimental pathological concepts and updates. Exp Mol Pathol 2015, 98:184-191.
47. Zhao J.S., Li W.J., Ge D., Zhang P.J., Li J.J., Lu C.L., et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 2011, 6:e21419.
48. Misra S., Hascall V.C., Berger F.G., Markwald R.R., Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res 2008, 49:219-224.
49. Misra S., Toole B.P., Ghatak S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem 2006, 281:34936-34941.
50. Gotoda T., Matsumura Y., Kondo H., Ono H., Kanamoto A., Kato H., et al. Expression of CD44 variants and prognosis in oesophageal squamous cell carcinoma. Gut 2000, 46:14-19.
51. Koyama S., Maruyama T., Adachi S. Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J Cancer Res Clin Oncol 1999, 125:47-54.
52. Liu W.K., Fu Q., Li Y.M., Jiang X.Y., Zhang M.P., Zhang Z.X. The relationship between cyclooxygenase-2, CD44v6, and nm23H1 in esophageal squamous cell carcinoma. Onkologie 2009, 32:574-578.
53. Moghbeli M., Moghbeli F., Forghanifard M.M., Abbaszadegan M.R. Cancer stem cell detection and isolation. Med Oncol 2014, 31:69.
54. Biddle A., Liang X., Gammon L., Fazil B., Harper L.J., Emich H., et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011, 71:5317-5326.
55. Qiao B., Gopalan V., Chen Z., Smith R.A., Tao Q., Lam A.K.Y. Epithelial-mesenchymal transition and mesenchymal-epithelial transition are essential for the acquisition of stem cell properties in hTERT-immortalised oral epithelial cells. Bio Cell 2012, 104:476-489.
56. Chute J.P., Muramoto G.G., Whitesides J., Colvin M., Safi R., Chao N.J., et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A 2006, 103:11707-11712.
57. Hess D.A., Wirthlin L., Craft T.P., Herrbrich P.E., Hohm S.A., Lahey R., et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006, 107:2162-2169.
58. Almanaa T.N., Geusz M.E., Jamasbi R.J. A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer 2013, 4:536-548.
59. Forghanifard M.M., Moaven O., Farshchian M., Montazer M., Raeisossadati R., Abdollahi A., et al. Expression analysis elucidates the roles of MAML1 and Twist1 in esophageal squamous cell carcinoma aggressiveness and metastasis. Ann Surg Oncol 2012, 19:743-749.
60. Moghbeli M., Abbaszadegan M.R., Farshchian M., Montazer M., Raeisossadati R., Abdollahi A., et al. Association of PYGO2 and EGFR in esophageal squamous cell carcinoma. Med Oncol 2013, 30:516.
61. Moghbeli M., Forghanifard M.M., Aarabi A., Mansourian A., Abbaszadegan M.R. Clinicopathological sex-related relevance of Musashi1 mRNA expression in esophageal squamous cell carcinoma patients. Pathol Oncol Res 2014, 20:427-433.
62. Moghbeli M., Moghbeli F., Forghanifard M.M., Garayali A., Abbaszadegan M.A. Cancer stem cell markers in esophageal cancer. AJCS 2013, 1:8-22.
63. Wu C., Alman B.A. Side population cells in human cancers. Cancer Lett 2008, 268:1-9.
64. Huang D., Gao Q., Guo L., Zhang C., Jiang W., Li H., et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009, 18:465-473.
65. Li H., Gao Q., Guo L., Lu S.H. The EN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther 2011, 11:950-958.
66. Okumura T., Tsunoda S., Mori Y., Ito T., Kikuchi K., Wang T.C., et al. The biological role of the low-affinity p75 neurotrophin receptor in esophageal squamous cell carcinoma. Clin Cancer Res 2006, 12:5096-5103.
67. Okumura T., Shimada Y., Imamura M., Yasumoto S. Neurotrophin receptor p75 (NTR) characterizes human esophageal keratinocyte stem cells in vitro. Oncogene 2003, 22:4017-4026.
68. He J., Liu Y., Zhu T., Zhu J., Dimeco F., Vescovi A.L., et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics 2012, 11. [M111.010744].
69. Tang K.H., Dai Y.D., Tong M., Chan Y.P., Kwan P.S., Fu L., et al. A CD90 tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 2013, 73:2322-2332.
70. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011, 17:313-319.
71. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001, 37:54-66.
72. Yang L., Ping Y.F., Yu X., Qian F., Guo Z.J., Qian C., et al. Gastric cancer stem-like cells possess higher capability of invasion and metastasis in association with a mesenchymal transition phenotype. Cancer Lett 2011, 310:46-52.
73. Yu S.C., Bian X.W. Enrichment of cancer stem cells based on heterogeneity of invasiveness. Stem Cell Rev 2009, 5:66-71.
74. Ye X.Z., Xu S.L., Xin Y.H., Yu S.C., Ping Y.F., Chen L., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol 2012, 189:444-453.
75. Yang L., Ren Y., Yu X., Qian F., Bian B.S., Xiao H.L., et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol 2014, 27:775-783.
76. Wang Y., Zhe H., Gao P., Zhang N., Li G., Qin J. Cancer stem cell marker ALDH1 expression is associated with lymph node metastasis and poor survival in esophageal squamous cell carcinoma: a study from high incidence area of northern China. Dis Esophagus 2012, 25:560-565.
77. Hwang C.C., Nieh S., Lai C.H., Tsai C.S., Chang L.C., Hua C.C., et al. A retrospective review of the prognostic value of ALDH-1. Bmi-1 and Nanog stem cell markers in esophageal squamous cell carcinoma. PLoS One 2014, 9:e105676.
78. Minato T., Yamamoto Y., Seike J., Yoshida T., Yamai H., Takechi H., et al. Aldehyde dehydrogenase 1 expression is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol 2013, 20:209-217.
79. Qiao D., Zeeman A.M., Deng W., Looijenga L.H., Lin H. Molecular characterization of hiwi, a human member of the piwi gene family whose overexpression is correlated to seminomas. Oncogene 2002, 21:3988-3999.
80. He W., Wang Z., Wang Q., Fan Q., Shou C., Wang J., et al. Expression of HIWI in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. BMC Cancer 2009, 9:426.
81. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet 2000, 24:372-376.
82. Nishimoto M., Miyagi S., Yamagishi T., Sakaguchi T., Niwa H., Muramatsu M., et al. Oct-3/4 maintains the proliferative embryonic stem cell state via specific binding to a variant octamer sequence in the regulatory region of the UTF1 locus. Mol Cell Biol 2005, 25:5084-5094.
83. Wang Q., He W., Lu C., Wang Z., Wang J., Giercksky K.E., et al. Oct 3/4 and SOX2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29:1233-1241.
84. Zhou X., Huang G.R., Hu P. Over-expression of Oct 4 in human esophageal squamous cell carcinoma. Mol Cells 2011, 32:39-45.
85. Pan G.J., Chang Z.Y., Scholer H.R., Pei D. Stem cell pluripotency and transcription factor Oct 4. Cell Res 2002, 12:321-329.
86. Vlaming M.L., Lagas J.S., Schinkel A.H. Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev 2009, 61:14-25.
87. Hang D., Dong H.C., Ning T., Dong B., Hou D.L., Xu W.G. Prognostic value of the stem cell markers CD133 and ABCG2 expression in esophageal squamous cell carcinoma. Dis Esophagus 2012, 25:638-644.
88. Tsunoda S., Okumura T., Ito T., Kondo K., Ortiz C., Tanaka E., et al. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology 2006, 71:251-258.
89. Rizzino A. SOX2 and Oct-3/4: a versatile pair of master regulators that orchestrate the self-renewal and pluripotency of embryonic stem cells. Wiley Interdiscip Rev Syst Biol Med 2009, 1:228-236.
90. Shahryari A., Rafiee M.R., Fouani Y., Oliae N.A., Samaei N.M., Shafiee M., et al. Two novel splice variants of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and Oct 4 in esophageal squamous cell carcinoma. Stem Cells 2014, 32:126-134.
91. Saigusa S., Mohri Y., Ohi M., Toiyama Y., Ishino Y., Okugawa Y., et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy. Oncol Rep 2011, 26:1069-1074.
92. Gen Y., Yasui K., Zen Y., Zen K., Dohi O., Endo M., et al. SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet 2010, 202:82-93.
93. Forghanifard M.M., Ardalan Khales S., Javdani-Mallak A., Rad A., Farshchian M., Abbaszadegan M.R. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma. Med Oncol 2014, 31:922.
94. Qiao B., Chen Z., Hu F., Tao Q., Lam A.K. BMI-1 activation is crucial in HTERT-induced epithelial-mesenchymal transition of oral epithelial cells. Exp Mol Pathol 2013, 95:57-61.
95. Siddique H.R., Saleem M. Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: preclinical and clinical evidences. Stem Cells 2012, 30:372-378.
96. Yoshikawa R., Tsujimura T., Tao L., Kamikonya N., Fujiwara Y. The oncoprotein and stem cell renewal factor BMI1 associates with poor clinical outcome in oesophageal cancer patients undergoing preoperative chemoradiotherapy. BMC Cancer 2012, 12:461.
97. Mitsui K., Tokuzawa Y., Itoh H., Segawa K., Murakami M., Takahashi K., et al. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003, 113:631-642.
98. Shimada Y., Okumura T., Sekine S., Moriyama M., Sawada S., Matsui K., et al. Expression analysis of iPS cell-inductive genes in esophageal squamous cell carcinoma by tissue microarray. Anticancer Res 2012, 32:5507-5514.
99. Sun L.L., Wu J.Y., Wu Z.Y., Shen J.H., Xu X.E., Chen B., et al. A three-gene signature and clinical outcome in esophageal squamous cell carcinoma. Int J Cancer 2015, 136:E569-E577.
100. Shmelkov S.V., Butler J.M., Hooper A.T., Hormigo A., Kushner J., Milde T. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.
101. Xia J., Zhang Y., Qian J., Zhu X., Zhang Y., Zhang J., et al. Isolation, identification and expression of specific human CD133 antibodies. Sci Rep 2013, 3:3320.
102. Okamoto H., Fujishima F., Nakamura Y., Zuguchi M., Ozawa Y., Takahashi Y., et al. Significance of CD133 expression in esophageal squamous cell carcinoma. World J Surg Oncol 2013, 11:51.
103. Zimmer G., Oeffner F., Von Messling V., Tschernig T., Gröness H.J., Klenk H.D., et al. Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J 1999, 341:277-284.
104. Dang Q., Liu J., Li J., Sun Y. Podoplanin: a novel regulator of tumor invasion and metastasis. Med Oncol 2014, 31:24.
105. Ma W., Wang K., Yang S., Wang J., Tan B., Bai B., et al. Clinicopathology significance of podoplanin immunoreactivity in esophageal squamous cell carcinoma. Int J Clin Exp Pathol 2014, 7:2361-2371.
106. Chao Y.K., Chuang W.Y., Yeh C.J., Wu Y.C., Liu Y.H., Hsieh M.J., et al. Prognostic significance of high podoplanin expression after chemoradiotherapy in esophageal squamous cell carcinoma patients. J Surg Oncol 2012, 105:183-188.
107. Tong L., Yuan S., Feng F., Zhang H. Role of podoplanin expression in esophageal squamous cell carcinoma: a retrospective study. Dis Esophagus 2012, 25:72-80.
108. Rahadiani N., Ikeda J., Makino T., Tian T., Qiu Y., Mamat S., et al. Tumorigenic role of podoplanin in esophageal squamous-cell carcinoma. Ann Surg Oncol 2010, 17:1311-1323.
109. Chuang W.Y., Yeh C.J., Wu Y.C., Chao Y.K., Liu Y.H., Tseng C.K., et al. Tumor cell expression of podoplanin correlates with nodal metastasis in esophageal squamous cell carcinoma. Histol Histopathol 2009, 24:1021-1027.
110. Baylin S.B., Jones P.A. A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011, 11:726-734.
111. Chaffer C.L., Brueckmann I., Scheel C., Kaestli A.J., Wiggins P.A., Rodrigues L.O., et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci U S A 2011, 108:7950-7955.
112. Chaffer C.L., Marjanovic N.D., Lee T., Bell G., Kleer C.G., Reinhardt F., et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013, 154:61-74.
113. Wang R., Chadalavada K., Wilshire J., Kowalik U., Hovinga K.E., Geber A., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
114. Lonardo E., Frias-Aldeguer J., Hermann P.C., Heeschen C. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012, 11:1282-1290.
115. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011, 71:614-624.
116. Vermeulen L., De Sousa E., Melo F., van der Heijden M., Cameron K., de Jong J.H., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010, 12:468-476.
117. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
118. Medema J.P. Cancer stem cells: the challenges ahead. Nat Cell Biol 2013, 15:338-344.
119. Eisenberg L.M., Eisenberg C.A. Stem cell plasticity, cell fusion, and transdifferentiation. Birth Defects Res C Embryo Today 2003, 69:209-218.
120. Tu L.C., Foltz G., Lin E., Hood L., Tian Q. Targeting stem cells-clinical implications for cancer therapy. Curr Stem Cell Res Ther 2009, 4:147-153.
121. Curtin J.C., Lorenzi M.V. Drug discovery approaches to target Wnt signaling in cancer stem cells. Oncotarget 2010, 1:563-577.
122. Pannuti A., Foreman K., Rizzo P., Osipo C., Golde T., Osborne B., et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 2010, 16:3141-3152.
123. Takebe N., Harris P.J., Warren R.Q., Ivy S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011, 8:97-106.
124. Sachlos E., Risueño R.M., Laronde S., Shapovalova Z., Lee J.H., Russell J., et al. Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 2012, 149:1284-1297.
125. Valent P., Bonnet D., De Maria R., Lapidot T., Copland M., Melo J.V., et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer 2012, 12:767-775.